Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

PreScription: Compounding with Cannabidiol

Author(s):  Allen Loyd V Jr

Issue:  Mar/Apr 2019 - Volume 23, Number 2
View All Articles in Issue

Page(s):  92

PreScription: Compounding with Cannabidiol Page 1

Download in electronic PDF format for $75

Abstract:  

Related Keywords: Loyd V. Allen Jr., PhD, RPh, CBD, cannabidiol, cannabinoids, US Food and Drug Administration, FDA, Cannabis sativa L., epilepsy, United States Pharmacopeia, USP, adverse effects

Related Categories: LEGAL, ADVERSE DRUG EVENTS

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
PreScription: Compounding with Cannabidiol
Allen Loyd V Jr
Mar/Apr 2019
Pg. 92

PreScription: Formal Appeals to United States Pharmacopeia Regarding USP Chapters <795>,<797>, and <825>: Part 1
Allen Loyd V Jr
Mar/Apr 2020
Pg. 92

PreScription: Formal Appeals to United States Pharmacopeia Regarding USP Chapters <795>, <797>, and <825>: Part 2
Allen Loyd V Jr
May/Jun 2020
Pg. 180

PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Allen Loyd V Jr
Sep/Oct 2017
Pg. 356

Rapid-Dissolve Technology: An Interview With Loyd V. Allen, Jr., PhD, RPh
Allen Loyd V Jr
Nov/Dec 2003
Pg. 449-450

Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines
Allen Loyd V Jr
Jul/Aug 2016
Pg. 351

View Sample
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances
Miller David G
Jul/Aug 2015
Pg. 303-305

The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone
Brunner Scott
Jan/Feb 2023
Pg. 22-23

Quality Assurance and Quality Control: Being Prepared for U.S. Food and Drug Administration Inspections and Staying in Compliance with United States Pharmacopeia Chapter <797>: Part 1
Martin Matt
Sep/Oct 2018
Pg. 401-404

PreScription: The Past (-->2020), The Present, and The Future (2021-->)
Allen Loyd V Jr
Mar/Apr 2021
Pg. 92

U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs
Allen Loyd V Jr
Nov/Dec 2015
Pg. 487-488

Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed
Brunner Scott
Jul/Aug 2020
Pg. 296-297

The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter
Miller David G
May/Jun 2014
Pg. 208

Quality Control: Minor Chapters, Major Impacts: What United States Pharmacopeia Chapters <51>, <61>, <62>, and <1207> Mean for Your Compounding Practice
Kelley Brian
Mar/Apr 2021
Pg. 115-124

PreScription: Permissible Exposure Limits and United States Pharmacopeia Chapter <800>
Allen Loyd V Jr
Sep/Oct 2021
Pg. 356

U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies
Yoch Doug
Mar/Apr 2017
Pg. 95-102

Basics of Compounding: Implementing United States Pharmacopeia Chapter <1163> Quality Assurance in Pharmaceutical Compounding, Part 1
Allen Loyd V Jr
Mar/Apr 2012
Pg. 146-150

Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1
Allen Loyd V Jr
Sep/Oct 2015
Pg. 389-390

PreScription: United States Pharmacopeia Chapter <800> Comments and Alternatives
Allen Loyd V Jr
May/Jun 2017
Pg. 180

U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line
Snow Stephen T
, Stannard Robert W, Bellis Jennifer, Moss Carrie A
Jan/Feb 2019
Pg. 32-33

Return to Top